Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › typical atrial flutter

Typical atrial flutter

Part of Atrial flutter

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for typical atrial flutter

4 trials tracked for typical atrial flutter: 2 in phase 3 or 4.

4Trials tracked
2Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 3 2 Other / NA 2
  1. Phase 3 Clinical Evaluation of Therapy™ Cool Path™ Duo Cardiac Ablation System for the Treatment of Typical Atrial Flutter (AFL) Completed
  2. Phase 3 Atrial Flutter Ablation With Contact Therapy Cool Path Ablation System Along With EnSite Velocity Contact System Completed
  3. N/A Therapy™ Cool Flex™ Irrigated Ablation System for Typical Atrial Flutter Completed
  4. N/A AcQBlate Force Sensing Ablation System US IDE for Atrial Flutter (AcQForce Flutter) Completed

Showing the 4 most-cited and recently-updated of 4 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Bipolar linear PFA shows similar safety to RFA for CTI ablation in persistent atrial fibrillation
Cardiology RCT
Bipolar linear PFA shows similar safety to RFA for CTI ablation in persistent atrial fibrillation PFA Ablation Matches Old Method With Less Time
This substudy RCT compared bipolar linear pulsed field ablation (PFA) with irrigated radiofrequency ablation (RFA) in 141 patients with pers…
Doctors can treat a specific heart rhythm problem faster with new technology without making it less safe.
Apr 16, 2026

Research across Atrial flutter

Related studies from across the Atrial flutter family.

SGLT2 inhibitors provide robust prognostic benefits in heart failure with inconsistent results in post-myocardial infarction settings
Cardiology Sys. Review
SGLT2 inhibitors provide robust prognostic benefits in heart failure with inconsistent results in post-myocardial infarction settings SGLT2 inhibitors show promise for heart failure and diabetes
This narrative review examines the cardiovascular and metabolic effects of SGLT2 inhibitors, specifically empagliflozin and dapagliflozin. T…
New evidence shows how SGLT2 inhibitors may protect the heart and manage risks for patients with type 2 diabetes and heart failure.
Frontiers Jun 9, 2026